We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
164 hedge funds and large institutions have $458M invested in Esperion Therapeutics in 2022 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 57 increasing their positions, 39 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
254% more call options, than puts
Call options by funds: $50.2M | Put options by funds: $14.2M
69% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 26
46% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 39
11% more funds holding
Funds holding: 148 → 164 (+16)
8% more capital invested
Capital invested by funds: $426M → $458M (+$32M)
4.54% more ownership
Funds ownership: 95.15% → 99.69% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
164
Holders Change
+16
Holders Change %
+10.81%
% of All Funds
2.64%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
44
Increased
57
Reduced
39
Closed
26
Calls
$50.2M
Puts
$14.2M
Net Calls
+$36M
Net Calls Change
+$17.6M
Top Buyers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$18.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.4M |
| 3 |
BlackRock
New York
|
+$6.8M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$6.47M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$5.77M |
Top Sellers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$11.7M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$11.5M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$5.52M |
| 4 |
Walleye Capital
New York
|
-$4.68M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$4.4M |
